ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 984,93
-0,99%
Dow Jones
37 815,92
0,00%
DAX
17 932,17
-1,10%
Brent Oil
85,145
-0,87%
Bitcoin
57 512,40
-5,10%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. REGENXBIO Inc (RGNX)

  7. REGENXBIO Inc (RGNX) Actualités

RGNX REGENXBIO Inc

15,35
0,00 (0,00%)
Avant marché
Dernière mise à jour : 13:00:05
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
REGENXBIO Inc RGNX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 15,35 13:00:05
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
15,35
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
01/5/202413:05PRNUSREGENXBIO to Host Conference Call on May 8 to Discuss First..
24/4/202413:05PRNUSREGENXBIO to Participate in Chardan's 8th Annual Genetic..
28/3/202412:05PRNUSREGENXBIO Announces Lancet Publication of Phase I/IIa Study..
27/3/202421:05PRNUSREGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD..
11/3/202413:00EDGAR2Form 8-K - Current report
11/3/202412:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
08/3/202412:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/3/202400:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202412:03EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
07/3/202405:20PRNUSREGENXBIO Announces Pricing of Upsized Public Offering of..
06/3/202422:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/3/202422:10PRNUSREGENXBIO Announces Proposed Public Offering of Common Stock
05/3/202422:26EDGAR2Form 144 - Report of proposed sale of securities
05/3/202413:05PRNUSREGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM..
29/2/202422:57PRNUSREGENXBIO to Host Webcast Event to Discuss New Interim..
27/2/202422:54EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202422:10EDGAR2Form 8-K - Current report
27/2/202422:05PRNUSREGENXBIO Reports Fourth Quarter and Full Year 2023..
21/2/202413:05PRNUSREGENXBIO to Host Conference Call on February 27 to Discuss..
17/2/202400:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202417:40PRNUSREGENXBIO Announces Pivotal Trial of RGX-121 for the..
07/2/202413:05PRNUSREGENXBIO Announces Completion of Enrollment in Cohort 2 and..
31/1/202413:05PRNUSREGENXBIO Announces Presentations at the 20th Annual..
19/1/202400:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/1/202422:22EDGAR2Form 144 - Report of proposed sale of securities
16/1/202420:47PRNUSREGENXBIO Announces Positive Interim Data from Phase II..
10/1/202413:05PRNUSREGENXBIO Announces Presentation at the Hawaiian Eye and..
08/1/202413:05PRNUSU.S. District Court Issues Decision on REGENXBIO and..
04/1/202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:21EDGAR2Form 144 - Report of proposed sale of securities
21/12/202319:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202322:29EDGAR2Form 144 - Report of proposed sale of securities
29/11/202313:05PRNUSREGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE®..
08/11/202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202322:10EDGAR2Form 8-K - Current report
08/11/202322:05PRNUSREGENXBIO Announces Updated Strategic Plans and Third..
07/11/202313:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
03/11/202323:53PRNUSREGENXBIO Presents Positive One Year Data from Phase II..
01/11/202312:05PRNUSREGENXBIO to Host Conference Call on November 8 to Discuss..
30/10/202312:05PRNUSREGENXBIO Announces Presentations at the American Academy of..
05/10/202313:05PRNUSREGENXBIO to Participate in the Jefferies CNS/Neuro Summit
03/10/202322:05PRNUSREGENXBIO Presents Interim Clinical Data from Phase I/II..
26/9/202313:05PRNUSREGENXBIO Announces Presentations at the 28th Annual..
05/9/202313:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
01/9/202322:42EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/9/202322:12EDGAR2Form 8-K - Current report
30/8/202313:05PRNUSInitial Clinical Data of First Pediatric CLN2 Patient Dosed..

Dernières Valeurs Consultées

NASDAQ
RGNX
REGENXBIO
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés